In the patients with metastatic colorectal cancer (mCRC), RAS testing is the first step to identify those that could benefit from anti-EGFR therapy. This study examined associations between KRAS mutations and clinicopathological and survival data in Iranian patients with mCRC. Between 2008 to2015 in a retrospective study, 83 cases of mCRC were referred to the Clinic of Medical Oncology. The mean follow-up was 45 months that there were 27 deaths. The 3 patients that did not complete follow-up were censored from the study. KRAS and NRAS were analyzed using allele-specific PCR primers and pyrosequencing in exons 2, 3 and 4. Multivariate survival analysis using Cox's regression model was used for affecting of variables on overall survival (OS). The mean age at diagnosis for patients was 57.7 (range, 18 to 80 years) and 61.4% were male. There was no significant different between prognostic factors and KRAS mutation with wild-type. Also, There was no significant different between KRAS mutation and KRAS wild-type for survival, but there was a significant different between KRAS 12 and 13 mutations for survival (HR 0.13, 95% CI 0.03-0.66, P=0.01). In conclusion, the prevalence of KRAS mutations in CRC patients was below 50% but higher than in other studies in Iran. As in many studies, patients with KRAS 12 mutations had better OS thn those with KRAS 13 mutation. In addition to KRAS testing, other biomarkers are needed to determine the best treatment for patients with mCRC.
Introduction
The development of colorectal cancer (CRC) is a multistep process that occurs because of the accumulation of several genetic alterations, including chromosomal abnormalities, gene mutations, and epigenetic modifications involving several genes that regulate proliferation, differentiation, apoptosis, and angiogenesis (Russo et al., 2009 ). In the patients of metastatic CRC (mCRC), RAS testing is the first step to identify those patients that could benefit from anti-EGFR therapy (Payandeh et al., 2016) . Mutation of the KRAS gene plays an important role in colorectal tumorigenesis (Li et al., 2012) . KRAS mutations in CRC have been stated to be 20-50% (Shen et al., 2011) . NRAS/BRAF mutation probably is effective in the treatment of CRC patients with KRAS wild-type and in patients with KRAS wild-type should be specified NRAS/BRAF testing to determine which patients will benefit from anti-EGFR therapy (Payandeh et al., 2015a) . There are very few studies about KRAS mutations in CRC from developing countries such as Iran (Omidifar et al., 2015 (Bokemeyer et al., 2009) . Totally, in retrospective analyzes have been shown that patients with KRAS wild-type had better OS compared to patients harboring KRAS mutation (Lievre et al., 2006) . This study examined associations between KRAS mutations and clinicopathological and survival data in Iranian patients with mCRC.
Materials and Methods

Patients
Between of 2008 to 2015 in a retrospective study, 83 patients with mCRC referred to Clinic of Medical Oncology, Kermanshah city, Iran. Age, sex, type of pathology, tumor size, differentiation, site of tumor and metastasis, KRAS/NRAS testing, lymph node metastasis and survival were checked. The mean follow-up was 45 months that there were 27 deaths and also 3 patients did not complete follow-up that censored from study. OS was defined from the date of diagnosis until death from any cause or the date of the last follow-up. Misinterpretation of results may occur if the information provided is inaccurate or incomplete. Every molecular test has a 0.5-1 % error rate. This is due to rare molecular events and factors related to the preparation and analysis of samples.
Analysis of KRAS/NRAS
Statistical analysis
Analysis of data was done by IBM SPSS version 19 (SPSS Inc., Chicago, IL, USA) software and survival diagram was plotted by GraphPad Prism version 5.04 software. Multivariate survival analysis using Cox's regression model was used for affecting of variables on OS. P-value<0.05 was considered statistically.
Results
The mean age at diagnosis for patients was 57.7±13 years (range, 18 to 80 years) that 51 patients (61.4%) were male (Table 1) . 50 patients (60.2%), 27(32.5%) and 6(7.3%) were well, moderate and poorly differentiated, respectively. Out of 83 patients, type of pathology in 51 patients (61.4%) were adenocarcinoma, site of tumor in 32 patients (38.6%) was rectum, KRAS testing for 46 patients (55.4%) was wild-type, NRAS testing for all patients was wild-type, site of metastasis for 55 patients (66.3%) was liver and lymph node metastasis for 55(71.4%) was positive. Table 2 shows the prevalence of KRAS mutations in exons 2, 3 and 4. G12D codon was the most mutation for codon 12 and G13D is only mutation in codon 13.
The correlation of prognostic factors between KRAS wild-type and KRAS mutation has been shown in Table  3 . There was no significant different between these factors and KRAS mutation with wild-type.
Median 5-year survival for KRAS mutation patients was 35 months and for KRAS wild type was 26 months (Figure 1) . Also, the survival rate for KRAS mutation and KRAS wild type was 69% and 64%, respectively. There was no significant different between KRAS mutation and KRAS wild-type for survival (HR 1.43, 95% CI 0.66-3.08, P=0.35).
Median 5-year survival in patients with KRAS codon 12 mutations was 55 and codon 13 mutation was 26 months (Figure 2) . Also, the survival rate for KRAS :http://dx.doi.org/10.7314/APJCP.2016.17.4 
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codon 12 mutations and codon 13 mutations was 79.3% and 28.5%, respectively. There was a significant different between KRAS 12 mutations and KRAS 13 mutation for survival (HR 0.13, 95% CI 0.03-0.66, P=0.01).
A Cox proportional hazard regression analysis was used to assess the effects of various parameters on the primary analysis. Male sex is an unfavorable predictor for OS of KRAS wild-type compared to KRAS mutation patients (Table 4) .
Discussion
Approximately 30% to 50% of colorectal tumors are known to have a mutated KRAS gene, indicating that up to 50% of patients with CRC might respond to anti-epidermal growth factor receptor (EGFR) antibody therapy. However, 40% to 60% of patients with wild-type KRAS tumors do not respond to such therapy (Wilson et al., 2010) . Based on 3 studies in Iran on CRC patients, the prevalence of KRAS mutation was between 12.5% in Tehran to 37.4% in this city (Central Iran) and also based on the studies in Asian other countries, between 23% in Thailand to 50% in Japan. In European countries, KRAS mutation was 30% in Italy to 49.3% in the UK, the USA (31.6%), Australia (28%), and African countries (23-28%). In this study (Western Iran), the prevalence was 44.6% (Omidifar et al., 2015) . Therefore, the results show that percentage of KRAS mutations in CRC patients is below of 50% and in our study was higher than other studies in Iran. In more studies, 12G>A was the most common substitution for KRAS Codon 12 (Omidifar et al., 2015) similar to our study. Therefore, ethnicity (Al-Kuraya, 2009; Sameer et al., 2009 ) and geography (Neumann et al., 2009; Brink et al., 2005) probably can effect on the prevalence of KRAS mutation.
Data from a large Japanese population of patients with advanced and recurrent CRC showed that the prevalence KRAS mutation is approximately 35% that 25% patients had mutations at codon 12 and 10% patients had mutations at codon 13 (Yokota et al., 2010) . Approximately 40% of CRCs harbor KRAS mutations, and 90% of those mutations occur in codons 12 and 13 (Roock et al., 2011) . Of 44.6% KRAS mutation in this study, KRAS codon 12 mutation (36.2%) was more than codon 13(8.4%). In one study (Li et al., 2012) , patients with KRAS wildtype had the significantly higher median survival times than patients with KRAS mutations (35.05 vs. 25.72 months). Another study (Margonis et al., 2015) , reported that median and 5-year survival rate among patients with KRAS mutation was 32.4 months and 32.7%, respectively, vs. 58.5 months and 46.9%, respectively, for patients with KRAS wild-type (P<0.05). A total of 99 patients with stage I-IV CRC, the cumulative 5-year survival rates for patients with KRAS wild-type, KRAS 12 and KRAS 13 mutations were 81.4, 61.4 and 42.0%, respectively (P<0.05) (Inoue et al., 2012) . Omidifar et al. (2015) showed that KRAS 13 mutation is associated with poor prognostic outcomes, including reduced survival rate, less stable cancer and disease relapse compared with codon 12 mutations. In the study of Margonis et al. (2015) , patients with KRAS 12 mutations had worse OS vs. those with KRAS wild-type, whereas a KRAS codon 13 mutation was not associated with prognosis. Compared with KRAS codon 12 mutations, codon 13-mutated mCRC presents as a more aggressive disease frequently associated with local and distant metastases at first diagnosis (Modest KRAS codon 12 mutation KRAS codon 13 mutation et al., 2011). In another research (Li et al., 2012) , has been reported that KRAS mutations at codons 12 or 13 did not have the significantly different median survival times. In our study, median and 5-year survival rate for KRAS mutation and KRAS wild-type were 35 months and 69%, respectively, 26 months and 64%, respectively. Also, patients with KRAS 12 mutations had better OS vs. those with KRAS 13 mutation that that agrees with our study. Median and survival rate for KRAS 12 mutations and codon 13 mutation was 55 months and 79.3%, respectively, vs. 26 months and 28.5%, respectively. OS in KRAS mutation/NRAS wild-type patients was higher than KRAS/NRAS wild-type (P>0.05), contrasting with the results of other studies (Tan and Du,2012; Payandeh et al., 2015b) . Multivariate survival analysis showed that male sex was an unfavorable predictor for OS. Allegra et al. (2016) reported that all patients with mCRC who are candidates for anti-EGFR therapy should have their tumor tested for mutations in both KRAS and NRAS. In addition to RAS testing, other biomarkers are needed to determine the best treatment for patients with mCRC, because the efficacy of anti-EGFR therapy, even in the RAS wildtype population, is modest. KRAS gene mutations were significantly associated with poor tumor differentiation and liver metastasis (Li et al., 2012) . In the study of Liu et al. (2011) , clinicopathologic features (age, sex, and tumor site, depth, size, grade, and metastasis) were not different between KRAS mutation and wild-type CRCs. In this study, there was no significant correlation between prognostic factors (age, sex, tumor size, differentiation, lymph node metastasis, type of pathology and tumor site) with KRAS mutation and wild-type. Therefore, the efficacy of anti-EGFR therapy is no suitable in all KRAS wild-type patients and we should be looking for other effective factors. In conclusions, the prevalence of KRAS mutations in CRC patients is below of 50% and in our study was higher than other studies in Iran. In a lot of studies, patients with KRAS 12 mutations had better OS vs. those with KRAS 13 mutation. In addition to KRAS/NRAS testing, other biomarkers are needed to determine the best treatment for patients with mCRC.
